A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)

Completed · Phase 2

Conditions studied: Atopic Dermatitis

In brief

The purpose of this study was to evaluate the pharmacokinetics and safety of nemolizumab in adolescent participants with AD.

Key facts

Study ID

NCT03921411

Run by

Galderma R&D

People needed

20

Starts

2019-04-09

Expected to finish

2020-08-19

Last updated by the study team

2023-04-21

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Galderma Investigational Site — Fountain Valley, California, United States
• Galderma Investigational Site — Fremont, California, United States
• Galderma Investigational Site — Jacksonville, Florida, United States
• Galderma Investigational Site — Tampa, Florida, United States
• Galderma Investigational Site — Columbus, Georgia, United States
• Galderma Investigational Site — Sandy Springs, Georgia, United States
• Galderma Investigational Site — Gresham, Oregon, United States
• Galderma Investigational Site — Dallas, Texas, United States
• Galderma Investigational Site — Frisco, Texas, United States
• Galderma Investigational Site — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.